Product Launch

Drug Approvals Need Shades Of Grey

FDA’s Endocrinologic and Metabolic drugs advisory committee on Nov. 8 voted 8-4 in favor of recommending Novo’s latest insulin degludec (Tresiba) for approval. The detailed debate and...

Learn More

Zaltrap: Now the Price is Right

Power to the payer. Just weeks after a team of Memorial Sloan Kettering Cancer Center physicians criticized the high price tag of Sanofi/Regeneron’s new angiogenesis inhibitor Zaltrap in a New York Times...

Learn More

The Healthcare Round-Up: 1/24 -1/31

Even as politicos geared up for today’s Florida primary, healthcare wonks are still shaking their heads at the fact that the Affordable Care Act –or healthcare generally—didn’t get much air time in President...

Learn More